|Title:||Method of inhibiting glycolipid synthesis|
|Abstract:||A method is disclosed for inhibiting the biosynthesis of glycolipids in cells capable of producing glycolipids comprising subjecting said cells to a glycolipid inhibitory effective amount of an N-alkyl derivative of 1,5-dideoxy-1,5-imino-D-glucitol in which said alkyl contains from 2-8 carbon atoms.|
|Inventor(s):||Platt; Frances M. (Oxford, GB), Neises; Gabrielle R. (Chesterfield, MO), Dwek; Raymond A. (Oxford, GB), Butters; Terry D. (Oxford, GB)|
|Assignee:||Monsanto Company (St. Louis, MO)|
1. The method of treating a patient affected with Gaucher's disease comprising administering to said patient a glycolipid inhibitory effective amount of an N-alkyl derivative
of 1,5-dideoxy-1,5-imino-D-glucitol in which said alky contains from 2-8 carbon atoms.
2. The method of claim 1 in which the alkyl group containing form 4-6 carbon atoms.
3. The method of claim 2 in which the alkyl group is butyl.
4. The method of claim 2 in which the alkyl group is hexyl.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.